BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 3.7% – Here’s What Happened

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares shot up 3.7% during trading on Friday . The company traded as high as $7.95 and last traded at $7.98. 1,042,637 shares traded hands during trading, a decline of 62% from the average session volume of 2,741,884 shares. The stock had previously closed at $7.69.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BCRX. Evercore ISI upped their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and set a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush began coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price for the company. JMP Securities restated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Trading Up 4.3 %

The firm has a 50 day moving average price of $8.12 and a 200-day moving average price of $7.83. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -13.17 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. The company’s revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.28 EPS. As a group, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System raised its holdings in shares of BioCryst Pharmaceuticals by 4.1% in the fourth quarter. California State Teachers Retirement System now owns 184,485 shares of the biotechnology company’s stock worth $1,387,000 after acquiring an additional 7,232 shares during the last quarter. Mackenzie Financial Corp raised its stake in BioCryst Pharmaceuticals by 190.7% in the 4th quarter. Mackenzie Financial Corp now owns 84,662 shares of the biotechnology company’s stock valued at $637,000 after purchasing an additional 55,535 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $33,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of BioCryst Pharmaceuticals by 3.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock worth $3,016,000 after purchasing an additional 11,581 shares during the last quarter. Finally, Woodline Partners LP purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $3,385,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.